EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

PD-L1 expression across urothelial carcinoma subtypes: A multicenter comparison of 22C3 and SP142 for clinical decision-making in the immunotherapy era

Juan Daniel Prieto Cuadra, Martina Álvarez Pérez, Pilar González-Peramato, Julián Sanz, Inés de Torres, Eugenia García Fernández, Adriana Zucchiatti, María José Lozano León, Elisa Matas Rico, María Isabel Hierro Martín

Pathology - Research and Practice · 2026

DOI: 10.1016/j.prp.2026.156372 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pathology - Research and Practice, 2026. Verfasst von Juan Daniel Prieto Cuadra und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, Virgen de la Victoria University Hospital, Malaga, Spain; Institute of Biomedical Research in Malaga (IBIMA-Plataforma BIONAND)…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Biomarkers, Tumor, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Urothelial carcinoma with histological subtypes (UC-s) presents diverse biological behaviours and therapeutic responses. PD-L1 immunoexpression has become a key biomarker for guiding immune checkpoint inhibitor therapy in advanced UC. However, the role of PD-L1 across UC-s remains limited characterized, with discrepancies reported between assays. OBJECTIVE: This multicenter retrospective study aimed to assess PD-L1 expression patterns in 169 UC-s cases using two assays (22C3 and SP142), with analysis of tumor cells (TC), immune cells (IC), combined positive score (CPS), interobserver variability, and to assess their diagnostic relevance. METHODS: Samples were obtained from five Spanish hospitals. Whole-slide immunohistochemistry was performed using both PD-L1 assays. Positivity thresholds were CPS ≥ 10 (22C3) and IC ≥ 5 % (SP142). Histological subtypes were subclassified and scoring was performed by four trained pathologists. RESULTS: PD-L1 expression varied widely among UC-s subtypes. Squamous and sarcomatoid subtypes showed the highest PD-L1 expression with both assays. A greater number of UC-s were positive with SP142, especially in IC, while 22C3 showed higher TC expression. Discordant cases highlighted the influence of assay and cellular compartment on PD-L1 status. Interobserver agreement was high. Notably, 27 cases were SP142-positive but 22C3-negative for IC, suggesting potential therapeutic implications. CONCLUSION: The 22C3 and SP142 assays show analytical concordance for overall PD-L1 status but significant variability in IC scoring. Given the variability in PD-L1 expression across UC-s, precise characterization of both TC and IC staining per assay is crucial. These findings support incorporating UC-s subtype and assay-specific PD-L1 profiles into routine diagnostics to optimize immunotherapy decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenBiomarkers, TumorCarcinoma, Transitional CellUrinary Bladder NeoplasmsClinical Decision-MakingHumansRetrospective StudiesFemaleMaleImmunohistochemistryImmunotherapyAgedMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

22C3HarmonisationPD-L1Precision personalized medicineSP142Subtypes urothelial carcinoma

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Pathology Department, Virgen de la Victoria University Hospital, Malaga, Spain; Institute of Biomedical Research in Malaga (IBIMA-Plataforma BIONAND), Virgen de la Victoria University Hospital, Malaga, Spain; Genitourin…
  • Institute of Biomedical Research in Malaga (IBIMA-Plataforma BIONAND), Virgen de la Victoria University Hospital, Malaga, Spain; Cancer Molecular Biology Laboratory, CIMES, University of Malaga, Malaga, Spain; Pathology…
  • Pathology Department, University Hospital La Paz, Universidad Autónoma de Madrid, Spain.
  • Department of Pathology, Cancer center Clínica Universidad de Navarra, Universidad de Navarra, Madrid, Spain.
  • Department of Pathology, Vall de Hebron University Hospital, Barcelona, Spain; Autonomous University of Barcelona (UAB), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
  • Department of Pathology, Vall de Hebron University Hospital, Barcelona, Spain.

Zitieren

APA

Cuadra, J. D. P., Pérez, M. Á., González-Peramato, P., Sanz, J., de Torres, I., Fernández, E. G., Zucchiatti, A., León, M. J. L., Rico, E. M., & Martín, M. I. H. (2026). PD-L1 expression across urothelial carcinoma subtypes: A multicenter comparison of 22C3 and SP142 for clinical decision-making in the immunotherapy era. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2026.156372

Vancouver

Cuadra JDP, Pérez MÁ, González-Peramato P, Sanz J, de Torres I, Fernández EG, et al. PD-L1 expression across urothelial carcinoma subtypes: A multicenter comparison of 22C3 and SP142 for clinical decision-making in the immunotherapy era. Pathology - Research and Practice. 2026. doi:10.1016/j.prp.2026.156372

BibTeX
@article{Cuadra2026,
  author = {Cuadra, Juan Daniel Prieto and Pérez, Martina Álvarez and González-Peramato, Pilar and Sanz, Julián and de Torres, Inés and Fernández, Eugenia García and Zucchiatti, Adriana and León, María José Lozano and Rico, Elisa Matas and Martín, María Isabel Hierro},
  title = {PD-L1 expression across urothelial carcinoma subtypes: A multicenter comparison of 22C3 and SP142 for clinical decision-making in the immunotherapy era},
  journal = {Pathology - Research and Practice},
  year = {2026},
  doi = {10.1016/j.prp.2026.156372}
}
Kostenlos starten →